Press Releases

Ablaze Pharmaceuticals, a biotech company that is focused on developing Targeted Radiotherapy  to benefit cancer patients in China, today announced the development plans of a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3 targeting peptide is being licensed from RayzeBio pursuant to an existing license agreement. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and commercialization of the p

ProBioGen, the Berlin-based CDMO and technology provider, reported today that revenues for the fiscal year 2022 (FY22) grew 35% vs FY21. In a year marked by new geopolitical and macroeconomic challenges, ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects. To support this influx of activities, ProBioGen recruited more than 80 new talents to close 2022 with over 300 employees and moved on in its full digital transforma

Juno Pharmaceuticals Canada a Canadian specialty pharmaceutical company, announces that it has received approval from Health Canada to import eptifibatide solution for infusion and injection pursuant to Health Canada guidelines for exceptional imports and sales. Juno has acquired a six-month supply for immediate distribution across the Canadian market to help replenish dangerously low inventory. Eptifibatide is prescribed to patients with certain types of acute coronary syndromes (d

SAI MedPartners a leading consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce it has acquired PharmaForce International (“PharmaForce”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022. PharmaForce, headquartered in Reading, PA, is a market intelligence firm that focuses on analyzing the sales, marketing, market access, and m

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for the Phase III clinical trial of its in-house developed first-in-class drug candidate KX-826 (pyrilutamide) in China for the treatment of male androgenetic alopecia (AGA) adults. The Phase III clinical trial is a randomized, double-blind, placebo-controlled, multi-r

The National Institute for Innovation in Manufacturing Biopharmaceuticals issues Part II of a whitepaper series titled Innovation of the Biopharmaceutical Manufacturing Talent Pipeline, a series focused on highlighting non-traditional and novel solutions for the talent pipeline gap in the biopharmaceutical industry. The newest whitepaper focuses on successes and challenges faced by community college biotechnology degree programs and makes the case for stronger engagement between industry and

The pharmaceutical excipients market in Asia is expected to continue to grow in the coming years. Factors contributing to this growth include the increasing demand for pharmaceuticals in the region, particularly generic drugs, and the growing focus on research and development in the pharmaceutical industry. Additionally, favorable government initiatives and investments in healthcare infrastructure in several Asian countries are expected to drive the growth of the pharmaceutical excipients mar

Biocept, Inc. a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide. This first patie The FORESEE trial is a multicenter, prospective clinical trial expected to enroll 40 patients with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM). The goal of the FORESEE trial

Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis. According to the American Cancer Society in 2022, the 5-year relative survival rate for localized breast cancer, cancer that has not spread outside the breast, is 99%, and for those whose cancer has spread outside the breast to nearby structures or lymph nodes, the survival rate is 86%. Over the last

ONO PHARMA USA, INC., announced that its candidate, tirabrutinib, a Bruton's tyrosine kinase inhibitor, was granted Orphan Drug Designation on March 21, 2023 by the U.S. Food and Drug Administration (FDA) for the treatment of patients with primary central nervous system lymphoma (PCNSL). The FDA's Orphan Drug Designation program supports the development and evaluation of investigational drugs and biologics that show promise for the diagnosis, treatment, or prevention of rare